

37. Inhaled therapies for tuberculosis

**THE 46TH UNION
WORLD CONFERENCE
ON LUNG HEALTH**

CAPE TOWN, SOUTH AFRICA
2-6 DECEMBER 2015

Saturday, 05 December 2015, 13:30 - 15:00

Room MR 2.41-2.43

Type of session	Symposium
Track	Drug-sensitive TB care and treatment, including trials
Track2 (optional)	Drug-resistant TB care and treatment, including trials
Description	As with asthma, inhaled anti-TB drugs and vaccines have the potential to revolutionise the way in which TB is treated. A number of research groups worldwide are addressing drug and vaccine delivery, and translation efforts are underway. What lessons have been learnt from lab-based research? Does targeting drugs to lung macrophages provide benefits? Can inhalations work as stand-alone therapy, replacing oral dosing? Is there scope to include inhalation as adjunct therapy in first-line treatment? This session will address these questions from research and policy perspectives.
Target audience	<ol style="list-style-type: none"> 1. Researchers in targeted drug delivery, mucosal immunisation and host-directed therapies for TB 2. Manufacturers, clinicians, regulatory professionals, policymakers and civil society 3. Domain-specific inputs on inhaled therapies for TB
Objectives	<ol style="list-style-type: none"> 1. To review and present the new and future perspectives on inhaled therapies for TB 2. To engage with clinicians, regulatory professionals, policymakers and civil society 3. To stimulate translational research and encourage pharmaceutical manufacturers to produce inhaled therapies
Keywords	Dry powder inhalations (DPI); alveolar macrophage, drug targeting; mucosal immunization; siRNA
Coordinator(s)	Mercedes Gonzalez-Juarrero (USA), Amit Misra (India)
Chair(s)	Anthony Hickey (USA), Bernard Fourie (South Africa)
Presentations	<p>13:30 - 13:40 Ways and means for inhaled drug delivery in TB Stefano Giovagnoli (Italy)</p> <p>13:45 - 13:55 Laboratory and non-clinical evaluation of pulmonary drug delivery in TB Amit Misra (India)</p> <p>14:00 - 14:10 The regulatory and policy landscape confronting manufacture, testing and registration of inhaled therapies for TB Anthony Hickey (USA)</p> <p>14:15 - 14:25 Clinical, epidemiological and patient compliance factors affecting deployment of inhaled therapies for TB in the field Bernard Fourie (South Africa)</p> <p>14:30 - 14:40 Design of clinical trials to assess safety and efficacy of inhaled therapies for TB and potential for 'therapeutic isolation' of TB patients Edward Nardell (USA)</p> <p>14:45 - 15:00 Discussion</p>